KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Other Accumulated Expenses (2017 - 2025)

Elanco Animal Health's Other Accumulated Expenses history spans 9 years, with the latest figure at $533.0 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 14.38% year-over-year to $533.0 million; the TTM value through Dec 2025 reached $533.0 million, up 14.38%, while the annual FY2025 figure was $533.0 million, 14.38% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $533.0 million at Elanco Animal Health, down from $665.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $685.0 million in Q3 2024 and bottomed at $377.0 million in Q1 2023.
  • The 5-year median for Other Accumulated Expenses is $506.0 million (2021), against an average of $512.2 million.
  • The largest YoY upside for Other Accumulated Expenses was 163.33% in 2021 against a maximum downside of 26.68% in 2021.
  • A 5-year view of Other Accumulated Expenses shows it stood at $430.0 million in 2021, then increased by 5.58% to $454.0 million in 2022, then dropped by 9.91% to $409.0 million in 2023, then increased by 13.94% to $466.0 million in 2024, then grew by 14.38% to $533.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELAN's Other Accumulated Expenses are $533.0 million (Q4 2025), $665.0 million (Q3 2025), and $596.0 million (Q2 2025).